[A22-135] Pembrolizumab (cervical cancer) – Addendum to Commission A22-70
Last updated 02.02.2023
Project no.:
A22-135
Commission:
Commission awarded on 21.12.2022 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Indication:
Adult patients with persistent, recurrent, or metastatic cervical cancer whose tumours express PD-L1 with a CPS ≥ 1
Result of dossier assessment:
- First-line patients for whom cisplatin or carboplatin + paclitaxel ± bevacizumab is a suitable therapy of physician’s choice: After addendum now: indication of major added benefit
- First-line patients for whom cisplatin or carboplatin + paclitaxel ± bevacizumab is no suitable therapy of physician’s choice: Unchanged after addendum: added benefit not proven
- Patients after first-line chemotherapy and for whom further antineoplastic therapy is an option: Unchanged after addendum: added benefit not proven
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A22-70 | Pembrolizumab (cervical cancer) – Benefit assessment according to § 35a SGB V | Commission completed |
Federal Joint Committee (G-BA)
2023-02-02 A G-BA decision was published.